The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Klen, Jasna ^a   Goričar, Katja ^b   Janež, Andrej ^c   Dolžan, Vita ^b  

^a Dialysis Department   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SULFONYLUREA; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; MATE1 PROTEIN, HUMAN; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; UREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEREDITY; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LIPID BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GENETICS; KIDNEY; LIVER; METABOLISM; MIDDLE AGED;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY; LIVER; MALE; METFORMIN; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; UREA;

EID: 84903555071     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/934729     Document Type: Article

References (37)

1. Erlich D. R., Slawson D. C., Shaughnessy A., Diabetes update: long-term treatment of adults. FP Essentials 2013 408 14 19 2-s2.0-84880444108
2. Rena G., Pearson E. R., Sakamoto K., Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013 56 9 1898 1906 2-s2.0-84881614717 10.1007/s00125-013-2991-0
3. Sin H. Y., Kim J. Y., Jung K. H., Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin. Archives of Pharmacal Research 2011 34 1 99 107 2-s2.0-79955057045 10.1007/s12272-011-0112-5
4. Inzucchi S. E., Bergenstal R. M., Buse J. B., Diamant M., Ferrannini E., Nauck M., Peters A. L., Tsapas A., Wender R., Matthews D. R., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012 55 6 1577 1596
5. Zolk O., Disposition of metformin: variability due to polymorphisms of organic cation transporters. Annals of Medicine 2012 44 2 119 129 2-s2.0-84857695519 10.3109/07853890.2010.549144
6. Shu Y., Brown C., Castro R. A., Shi R. J., Lin E. T., Owen R. P., Sheardown S. A., Yue L., Burchard E. G., Brett C. M., Giacomini K. M., Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clinical Pharmacology and Therapeutics 2008 83 2 273 280 2-s2.0-38349085099 10.1038/sj.clpt.6100275
7. Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., Furlong T. J., Greenfield J. R., Greenup L. C., Kirkpatrick C. M., Ray J. E., Timmins P., Williams K. M., Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics 2011 50 2 81 98 2-s2.0-78751500357 10.2165/11534750-000000000- 00000
8. Zolk O., Current understanding of the pharmacogenomics of metformin. Clinical Pharmacology and Therapeutics 2009 86 6 595 598 2-s2.0-70450149001 10.1038/clpt.2009.144
9. Tzvetkov M. V., Vormfelde S. V., Balen D., Meineke I., Schmidt T., Sehrt D., Sabolić I., Koepsell H., Brockmöller J., The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clinical Pharmacology and Therapeutics 2009 86 3 299 306 2-s2.0-69449098951 10.1038/clpt.2009.92
10. Lozano E., Herraez E., Briz O., Robledo V. S., Hernandez-Iglesias J., Gonzalez-Hernandez A., Marin J. J. G., Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. BioMed Research International 2013 2013 13 2-s2.0-84883167778 10.1155/2013/692071 692071
11. Otsuka M., Matsumoto T., Morimoto R., Arioka S., Omote H., Moriyama Y., A human transporter protein that mediates the final excretion step for toxic organic cations. Proceedings of the National Academy of Sciences of the United States of America 2005 102 50 17923 17928 2-s2.0-29144523534 10.1073/pnas.0506483102 (Pubitemid 41798478)
12. Tsuda M., Terada T., Mizuno T., Katsura T., Shimakura J., Inui K.-I., Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Molecular Pharmacology 2009 75 6 1280 1286 2-s2.0-66849142125 10.1124/mol.109.056242
13. Motohashi H., Inui K.-I., Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS Journal 2013 15 2 581 588 2-s2.0-84877026119 10.1208/s12248-013-9465-7
14. Kerb R., Brinkmann U., Chatskaia N., Gorbunov D., Gorboulev V., Mornhinweg E., Keil A., Eichelbaum M., Koepsell H., Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002 12 8 591 595 2-s2.0-0036865724 10.1097/00008571-200211000-00002 (Pubitemid 36005667)
15. Shu Y., Sheardown S. A., Brown C., Owen R. P., Zhang S., Castro R. A., Ianculescu A. G., Yue L., Lo J. C., Burchard E. G., Brett C. M., Giacomini K. M., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 2007 117 5 1422 1431 2-s2.0-34248156160 10.1172/JCI30558 (Pubitemid 46718430)
16. Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics Journal 2009 9 4 242 247 2-s2.0-67849116869 10.1038/tpj.2009.15
17. Chen L., Takizawa M., Chen E., Schlessinger A., Segenthelar J., Choi J. H., Sali A., Kubo M., Nakamura S., Iwamoto Y., Iwasaki N., Giacomini K. M., Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. Journal of Pharmacology and Experimental Therapeutics 2010 335 1 42 50 2-s2.0-77957238214 10.1124/jpet.110.170159
18. Umamaheswaran G., Praveen R. G., Arunkumar A. S., Das A. K., Shewade D. G., Adithan C., Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian Journal of Human Genetics 2011 17 3 164 168 2-s2.0-84856385546 10.4103/0971-6866.92094
19. Nies A. T., Koepsell H., Winter S., Burk O., Klein K., Kerb R., Zanger U. M., Keppler D., Schwab M., Schaeffeler E., Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009 50 4 1227 1240 2-s2.0-70350075408 10.1002/hep.23103
20. Shikata E., Yamamoto R., Takane H., Shigemasa C., Ikeda T., Otsubo K., Ieiri I., Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. Journal of Human Genetics 2007 52 2 117 122 2-s2.0-33846617263 10.1007/s10038-006-0087-0 (Pubitemid 46185105)
21. Zhou K., Bellenguez C., Spencer C. C. A., Bennett A. J., Coleman R. L., Tavendale R., Hawley S. A., Donnelly L. A., Schofield C., Groves C. J., Burch L., Carr F., Strange A., Freeman C., Blackwell J. M., Bramon E., Brown M. A., Casas J. P., Corvin A., Craddock N., Deloukas P., Dronov S., Duncanson A., Edkins S., Gray E., Hunt S., Jankowski J., Langford C., Markus H. S., Mathew C. G., Plomin R., Rautanen A., Sawcer S. J., Samani N. J., Trembath R., Viswanathan A. C., Wood N. W., Harries L. W., Hattersley A. T., Doney A. S. F., Colhoun H., Morris A. D., Sutherland C., Hardie D. G., Peltonen L., McCarthy M. I., Holman R. R., Palmer C. N. A., Donnelly P., Pearson E. R., Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics 2011 43 2 117 120 2-s2.0-79251612707 10.1038/ng.735
22. Standards of medical care in diabetes-2010. Diabetes Care 2010 33 supplement 1 S11 S61
23. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013 36 supplement 1 S67 S74
24. Klen J., Dolzan V., Janez A., CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European Journal of Clinical Pharmacology 2014 70 4 421 428 10.1007/s00228-014-1641-x
25. Cryer P. E., Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia. Diabetes Care 2005 28 5 1245 1249 2-s2.0-18144388647 10.2337/diacare.28.5.1245 (Pubitemid 40616648)
26. Seaquist E. R., Anderson J., Childs B., Cryer P., Dagogo-Jack S., Fish L., Heller S. R., Rodriguez H., Rosenzweig J., Vigersky R., Hypoglycemia and diabetes: a report of aworkgroup of the American diabetes association and the endocrine society. Diabetes Care 2013 36 5 1384 1395 2-s2.0-84876796916 10.2337/dc12-2480
27. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 1999 130 6 461 470 2-s2.0-0033574249 (Pubitemid 29135798)
28. Levey A. S., Eckardt K.-U., Tsukamoto Y., Levin A., Coresh J., Rossert J., De Zeeuw D., Hostetter T. H., Lameire N., Eknoyan G., Willis K., Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2005 67 6 2089 2100 2-s2.0-23044448585 10.1111/j.1523-1755.2005.00365.x (Pubitemid 41623371)
29. Becker M. L., Visser L. E., Van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenetics and Genomics 2010 20 1 38 44 2-s2.0-73949087018 10.1097/FPC.0b013e328333bb11
30. Tkáč I., Klimčáková L., Javorský M., Fabianová M., Schroner Z., Hermanová H., Babjaková E., Tkáčová R., Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes, Obesity and Metabolism 2013 15 2 189 191 2-s2.0-84871937263 10.1111/j.1463-1326.2012.01691.x
31. Zhou K., Donnelly L. A., Kimber C. H., Donnan P. T., Doney A. S. F., Leese G., Hattersley A. T., McCarthy M. I., Morris A. D., Palmer C. N. A., Pearson E. R., Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009 58 6 1434 1439 2-s2.0-66649121405 10.2337/db08-0896
32. Kahn S. E., Haffner S. M., Heise M. A., Herman W. H., Holman R. R., Jones N. P., Kravitz B. G., Lachin J. M., O'Neill M. C., Zinman B., Viberti G., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 2006 355 23 2427 2443 2-s2.0-33845405222 10.1056/NEJMoa066224 (Pubitemid 44903747)
33. Duong J. K., Kumar S. S., Kirkpatrick C. M., Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clinical Pharmacokinetics 2013 52 5 373 384 10.1007/s40262-013-0046-9
34. Kooy A., De Jager J., Lehert P., Bets D., Wulffelé M. G., Donker A. J. M., Stehouwer C. D. A., Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Archives of Internal Medicine 2009 169 6 616 625 2-s2.0-63849328978 10.1001/archinternmed.2009.20
35. Ji L., Li H., Guo X., Li Y., Hu R., Zhu Z., Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS ONE 2013 8 2 2-s2.0-84874545012 10.1371/journal.pone.0057222 e57222
36. Lund S. S., Tarnow L., Astrup A. S., Hovind P., Jacobsen P. K., Alibegovic A. C., Parving I., Pietraszek L., Frandsen M., Rossing P., Parving H. H., Vaag A. A., Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes, Obesity and Metabolism 2009 11 10 966 977 2-s2.0-70349762895 10.1111/j.1463-1326.2009.01079.x
37. Tarasova L., Kalnina I., Geldnere K., Bumbure A., Ritenberga R., Nikitina-Zake L., Fridmanis D., Vaivade I., Pirags V., Klovins J., Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenetics and Genomics 2012 22 9 659 666 2-s2.0-84864950319 10.1097/FPC.0b013e3283561666